Consensus Points at the ACCC Institute for the Future of Oncology Forum


Get Permission

Richard Pazdur, MD

Deborah Armstrong, MD

Josh Sommer

Mace Rothenberg, MD

Richard Simon, DSc

Richard L. Schilsky, MD, FACP, FASCO

Gideon Blumenthal, MD

Dane Dickson, MD

One of the major challenges to implementing personalized medicine is the lack of information about the risks and benefits of targeted drugs that are used off-label to treat patients whose tumor harbors a genomic abnormality.

Richard L. Schilsky, MD, FACP, FASCO
Response rate is not just a surrogate measure, it is a real-world clinical tool for patient assessment. Significant and prolonged reduction of tumor burden is clinically meaningful and could be used for regulatory approval.

Gideon Blumenthal, MD

Forum participants agreed that:

  • Defining quality in cancer care is challenging.
  • Each stakeholder group—practitioners, payers, patients—has its own definition of quality.
  • Given the growing number of accrediting/quality improvement organizations/standards and reporting requirements, some streamlining or consolidating of these programs would be beneficial.
  • Patients often define quality by nonclinical parameters, such as environment of care and communication with provider.
  • The current reimbursement climate does not incentivize many of the approaches that improve quality.
  • Cost and quality must be considered in tandem when determining value. ■

Related Articles

Transitioning From Volume to Value in Cancer Care

In an oncology health-care system that is increasingly changing its delivery and payment models, how do busy oncologists successfully bridge the transition from a volume- to value-based, patient-centric model? This, and other topics on value fueled a robust discussion at the Association of...


Advertisement

Advertisement



Advertisement